Total Funding
89
24
Total FundingSeries C raised
Growth Score
-7 pts
Heat Score
-29 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8320
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
- Robert MacLaren: Scientific Founder and Director
- Ryan Robinson: Chief Financial OfficerPast Role: Tourmaline Bio, Chief Financial Officer & Treasurer
About the Company
Beacon Therapeutics is a biotechnology firm in the clinical stage focused on preserving and enhancing vision for individuals affected by both uncommon and widespread eye disorders. The organization is leveraging the revolutionary potential of gene therapy to achieve significant results for serious eye conditions. Currently, Beacon's pipeline
is aimed at severe retinal diseases that cause blindness, including X-linked retinitis pigmentosa (XLRP) and geographic atrophy.
